China’s Long-Awaited Reimbursement Mechanism for Pharma Products

China’s reimbursement mechanism for innovative pharmaceutical products

China’s pharma market is second only to that of the US, but China’s environment is highly competitive in terms of pricing and reimbursement of pharmaceutical products. Recent changes to China’s reimbursement policies, including frequent updates to the National Reimbursed Drug List (NRDL) and the inclusion of 250+ innovative products in the NRDL, make it a lucrative destination for pharmaceutical companies. In this insight paper, we cover the following:

  • China’s governing bodies and reimbursement mechanisms and policies
  • Parameters used for reimbursement pricing
  • The 15% rule and how China’s reimbursement process differs from other countries’
  • Recent price cuts for products that made it to the NRDL
  • PD-1 inhibitors that made it to the NRDL

Key Takeaways

  • The NRDL has been updated annually since 2017
  • There are no separate Provincial Reimbursed Drug Lists (PRDLs); the provinces have been given until 2022 to consolidate their lists
  • Time to reimbursement from product launch decreased significantly to 1.3 years in 2020 from 4.7 years in 2017
  • Manufacturers are not allowed to apply for listing their products on the NRDL; the list of potential drugs is selected by an expert committee
  • The National Healthcare Security Administration (NHSA) very likely benchmarks the pricing to the lowest price of international reference pricing from a basket of 12 recommended countries
  • Negotiations will be conducted only for those products whose manufacturer’s offer price falls within 15% of the target price set by the expert committee
  • The average discount since 2017 has been a little over 50% for products included in the NRDL; this puts significant pressure on manufacturers

Originally published at


Raghu Patale serves as Delivery Manager leading the Life Sciences Corporate Strategy Research and Consulting vertical. His responsibilities include thought leadership, setting up new client engagements, client management, and generating business insights. He has over 10 years of experience in conducting life science research as a competitive intelligence and strategy consultant. He has supported a wide spectrum of client engagements focusing on competitive intelligence, therapy area research, market opportunity assessments, M&A support and report writing in oncology and other therapy areas for US, EU5, and Asian geographies.

Prior to this, Raghu was a Group Manager, leading the Pharma Practice at Evalueserve. He holds a Master’s degree in Pharmaceutical Sciences from the National Institute of Pharmaceutical Education and Research (NIPER).




We write about financial industry trends, the impact of regulatory changes and opinions on industry inflection points.

Love podcasts or audiobooks? Learn on the go with our new app.

Recommended from Medium

Healthcare — Medical Science or Healing Art?

Please! Don’t Rush it.

Trial by Data: Fixing the Patient Pipeline

How has the pandemic affected you mentally?

Atlanta 3-year-old rolls up sleeve to test COVID-19 vaccine

Sleep Apnea Machine Helps You Sleep Well

Tesco Life Insurance Review in Highams Park #Personal #Insurance #from #Tesco #Highams #Park…

Difference between Foam Mattresses and LatexMattresses.

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Acuity Knowledge Partners

Acuity Knowledge Partners

We write about financial industry trends, the impact of regulatory changes and opinions on industry inflection points.

More from Medium

Data: If You Can’t Buy it, Own it.

How AI is Transforming The Future of Healthcare 🔮

Analyzing Food Insecurity in the United States

UPI Lite — UPI without Internet — 21 FAQs